Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented challenge to the US healthcare system. In a blog post ...

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...

In the past few years, pharmaceutical companies have produced a class of drugs that lower cholesterol by inhibiting a protein called PCSK9 in a new attempt to reduce the risk of heart disease, the ...

The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes ...

Inhibitors of LDL synthesis, lomitapide and mipomersen, are new therapeutic options. PCSK9 inhibitors are being evaluated in HoFH and seem to be effective if there is residual receptor activity.

an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis and Daiichi-Sankyo-partnered antibody drug conjugates (ADCs). Declining Sales of Gardasil in ...

These drugs reduce the cholesterol your body makes ... get rid of cholesterol in the body and typically reduce LDL levels by 15-30% PCSK9 inhibitors -- alirocumab (Praluent), evolocumab (Repatha ...

PCSK9 inhibitors are another medication. “PCSK9 inhibitors are drugs that block the PCSK9 protein, which reduces LDL receptor breakdown and increases their recycling, helping lower LDL ...

So in these three trials, Patients, everyone received a statin but half the group received a placebo drug Jyoti Sharma continued... and the other half received the PCSK9 inhibitors. And what we ...

Inhibition of PCSK9 suppressed breast cancer metastasis ... a safe and well-tolerated drug, for metastasis prevention in patients with inherited PCSK9 mutations.